Ignite Creation Date:
2025-12-26 @ 11:10 AM
Ignite Modification Date:
2026-02-26 @ 8:12 PM
Study NCT ID:
NCT00675012
Status:
COMPLETED
Last Update Posted:
2014-05-30
First Post:
2008-05-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003110', 'term': 'Colonic Neoplasms'}], 'ancestors': [{'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C464839', 'term': 'tumor necrosis factor-alpha, CNGRC fusion protein, human'}, {'id': 'D000077150', 'term': 'Oxaliplatin'}, {'id': 'D000069287', 'term': 'Capecitabine'}], 'ancestors': [{'id': 'D056831', 'term': 'Coordination Complexes'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 24}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-05', 'completionDateStruct': {'date': '2013-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-05-29', 'studyFirstSubmitDate': '2008-05-05', 'studyFirstSubmitQcDate': '2008-05-06', 'lastUpdatePostDateStruct': {'date': '2014-05-30', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-05-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2010-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.', 'timeFrame': 'during the study'}], 'secondaryOutcomes': [{'measure': 'Document the preliminary antitumor activity in terms of objective response rate (according to RECIST criteria) and progression-free survival', 'timeFrame': 'during the study'}, {'measure': 'Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII', 'timeFrame': 'before during and following the treatment'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['NGR-hTNF', 'Capecitabine', 'Oxaliplatin', 'Colon cancer'], 'conditions': ['Colon Cancer']}, 'referencesModule': {'references': [{'pmid': '20855468', 'type': 'RESULT', 'citation': 'Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Ann Oncol. 2011 Apr;22(4):973-978. doi: 10.1093/annonc/mdq436. Epub 2010 Sep 20.'}]}, 'descriptionModule': {'briefSummary': 'The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any clinical improvement by current standard treatments', 'detailedDescription': 'Phase II, open-label, non-randomized study that will be conducted in two sequential cohorts of patients. Patients with metastatic colorectal cancer not amenable to any clinical improvement by current standard treatments are planned to be enrolled.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients ≥ 18 years with metastatic colorectal cancer (CRC) treated with no more than three standard systemic regimens (including biologic agents) for metastatic disease\n* Life expectancy more than 3 months\n* ECOG Performance status 0-1\n* Adequate baseline bone marrow, hepatic and renal function, defined as follows:\n\n * Neutrophils \\>1.5 x 10\\^9/L and platelets \\> 100 x 10\\^9/L\n * Bilirubin \\<1.5 x ULN\n * AST and/or ALT \\<2.5 x ULN in absence of liver metastasis\n * AST and/or ALT \\<5 x ULN in presence of liver metastasis\n * Serum creatinine \\<1.5 x ULN\n * Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min\n* Patients may have had prior therapy providing the following conditions are met:\n\n * Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days before start treatment\n * Surgery: wash-out period of 14 days before start treatment\n* Patients must give written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Concurrent anticancer therapy\n* Patients must not receive any other investigational agents while on study\n* Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication\n* Uncontrolled hypertension\n* Prolonged QTc interval (congenital or acquired)\n* Patient with significant peripheral vascular disease\n* Clinical signs of CNS involvement\n* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol\n* Symptomatic peripheral neuropathy ≥ grade 1 according the NCI CTCAE v.3.0.\n* Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients\n* Known hypersensitivity/allergic reaction or contraindications to platinum compounds or fluoropyrimidines\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol\n* Pregnancy or lactation.\n* Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study.\n* Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration'}, 'identificationModule': {'nctId': 'NCT00675012', 'briefTitle': 'NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer', 'organization': {'class': 'INDUSTRY', 'fullName': 'AGC Biologics S.p.A.'}, 'officialTitle': 'NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer', 'orgStudyIdInfo': {'id': 'NGR005'}, 'secondaryIdInfos': [{'id': '2007-003668-24', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'A', 'interventionNames': ['Drug: NGR-hTNF', 'Drug: Oxaliplatin', 'Drug: capecitabine']}], 'interventions': [{'name': 'NGR-hTNF', 'type': 'DRUG', 'description': 'iv 0.8 or 45 mcg/sqm q3W', 'armGroupLabels': ['A']}, {'name': 'Oxaliplatin', 'type': 'DRUG', 'description': 'iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion', 'armGroupLabels': ['A']}, {'name': 'capecitabine', 'type': 'DRUG', 'description': 'orally 825 mg/sqm 2qDx14', 'armGroupLabels': ['A']}]}, 'contactsLocationsModule': {'locations': [{'zip': '16132', 'city': 'Genoa', 'state': 'Genoa', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Universitaria San Martino', 'geoPoint': {'lat': 44.40478, 'lon': 8.94439}}], 'overallOfficials': [{'name': 'Alberto Sobrero, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Azienda Ospedaliera Universitaria San Martino Genoa, Italy'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AGC Biologics S.p.A.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}